CEST MRI methods for imaging of metabolites and the use of same as biomarkers
The CEST effect for various neurotransmitters and energy metabolites in the brain and muscles and various endogenous metabolites in the liver, brain, and myocardium are imaged using MR imaging to illustrate a unique CEST effect that may be used to monitor the concentration of the metabolite and hence to characterize and monitor various disease states in the body correlated to the concentration of that metabolite. By adjusting the timing, amplitude, and length of the RF pulse as well as other parameters of the CEST pulse sequence to address the unique chemical shifts and exchange rates of the target, new targets with unique characteristics may be acquired using CEST MR imaging.
1. A method of obtaining the concentration of metabolites within the body using MR imaging, comprising:
applying a Chemical Exchange Saturation Transfer (CEST) saturation pulse train at a range of frequency offsets around a frequency of exchangeable protons of a target metabolite as well as the same frequency offsets on the opposite of the water resonance;
MR imaging a slice of the body containing the target metabolite to which the CEST saturation pulse has been applied;
determining a CEST contrast image by taking a ratio of a difference image obtained by subtraction of saturation images obtained with saturation applied at both positive and negative frequencies with respect to water resonance and an image with no saturation; and
displaying the CEST contrast image.
2. The method of claim 1 , further comprising adjusting an amplitude and duration of the CEST saturation pulse train based on the proton exchange rate of the target metabolite.
3. The method of claim 1 , wherein the CEST saturation pulse train comprises a variable number of pulses with variable shapes including rectangle and Hanning windowed rectangle, variable amplitudes, variable durations, and variable delays.
4. The method of claim 1 , further comprising B 0 and B 1 correcting the saturation images before subtracting said saturation images.
5. The method of claim 1 , wherein the target metabolite is at least one of gamma-aminobutyric acid, glutamate, myo-inositol, adenosine triphosphate (ATP), phospho-creatine, creatine, glycine, proline, albumin, alanine, and aspartate.
6. The method of claim 1 , comprising the further step of using the concentration of the metabolite in the subtraction image as a biomarker for monitoring disease states correlated to the metabolite concentration.
7. The method of claim 1 , wherein the image slice is taken from a subject's liver, comprising the further step of staging liver fibrosis and characterizing liver function by monitoring changes in the concentration of liver metabolites including proline, albumin, aspartate, and/or alanine in the CEST contrast image.
8. The method of claim 1 , wherein the image slice is taken from a subject's myocardium, comprising the further step of differentiating non-infarcted viable myocardial tissue from infarcted tissue by measuring changes in the concentration of creatine in the subtraction image.
9. The method of claim 8 , comprising the further step of measuring pH changes in the myocardial tissue to distinguish a region of the myocardium that is partially ischemic from non-infarcted myocardial viable myocardial tissue.
10. The method of claim 1 , comprising the further steps of inducing stress in the myocardium and monitoring changes in the creatine levels in response to stress in the CEST contrast image.
11. The method of claim 1 , wherein the image slice is taken from a subject's brain, comprising the further step of monitoring relative changes in levels of myo-inositol in the subject's brain.
12. The method of claim 11 , comprising the further step of using the concentration of myo-inositol in the subtraction image as a biomarker for monitoring disease states correlated to the concentration of myo-inositol in the subject's brain, progression of said disease states, and/or efficacy of treatment of said disease states.
13. The method of claim 12 , wherein the concentration of myo-inositol is used as a biomarker for monitoring the progression and/or the efficacy of treatment of Alzheimer's Disease.
14. The method of claim 11 , comprising the further step of measuring pH changes in the brain to distinguish a region of hypoxia and stroke that is partially ischemic from healthy brain tissue.
15. The method of claim 1 , wherein the image slice is taken from a subject's skeletal muscle, comprising the further step of differentiating well perfused muscle tissue from under perfused muscle tissue by measuring changes in the concentration of creatine in the subtraction image.
16. The method of claim 1 , comprising the further steps of inducing stress in the muscle tissue and monitoring changes in the creatine levels in response to stress in the CEST contrast image.
17. A system for obtaining the concentration of metabolites within the body using MR imaging, comprising:
an MR scanner for imaging a subject's body;
an imaging controller that generates a Chemical Exchange Saturation Transfer (CEST) saturation pulse train at a range of frequency offsets around a frequency of exchangeable protons of a target metabolite as well as the same frequency offsets on the opposite of the water resonance and applies said CEST saturation pulse to said MR scanner for MR imaging a slice of the subject's body containing the target metabolite to which the CEST saturation pulse has been applied, and that determines a CEST contrast image by taking a ratio of a difference image obtained by subtraction of saturation images obtained with saturation applied at both positive and negative frequencies with respect to water resonance and an image with no saturation; and
a display that displays the CEST contrast image.
18. The system of claim 17 , wherein the imaging controller adjusts an amplitude and duration of the CEST saturation pulse train based on the proton exchange rate of the target metabolite.
19. The system of claim 17 , wherein the CEST saturation pulse train comprises a variable number of pulses with variable shapes including rectangle and Hanning windowed rectangle, variable amplitudes, variable durations, and variable delays.
20. The system of claim 1 , wherein the saturation images are B 0 and B 1 corrected saturation images.
21. The system of claim 17 , wherein the target metabolite is at least one of gamma-aminobutyric acid, glutamate, myo-inositol, adenosine triphosphate (ATP), phospho-creatine, creatine, glycine, proline, albumin, alanine, and aspartate.